Treatment of Nonmetastatic Anal Canal Squamous Cell Carcinoma Without Distant Metastasis

This protocol addresses patients with squamous cell carcinoma of the anal canal who have no evidence of distant metastasis and are able to tolerate a mitomycin-based concurrent chemoradiation regimen.

Clinical Scenario

Concurrent chemoradiation is the established primary treatment approach for nonmetastatic anal canal squamous cell carcinoma. The protocol applies to locoregional disease where the patient's performance status permits a mitomycin-based concurrent regimen.

Treatment Approach (Partial Overview)

The backbone of treatment is concurrent chemoradiation. A mitomycin-containing chemotherapy combination delivered alongside radiation therapy is the standard approach, with an alternative platinum-containing combination also recognised (category 2B). Radiation dose requirements and boost thresholds depend on disease staging. The complete regimen, drug sequencing, scheduling, and dose specifications are detailed in the full structured protocol.

Treatment Goal

The primary aim is complete remission of disease, assessed by digital rectal examination (DRE) performed between 8 and 12 weeks after completion of chemoradiation.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.6004/jnccn.2023.0030

Currently, concurrent chemoRT is the recommended primary treatment of patients with nonmetastatic anal canal cancer as well as for patients with positive para-aortic lymph nodes that can be included in the radiation field, although only limited retrospective data support use in this setting.
Mitomycin/5-FU or mitomycin/capecitabine is administered concurrently with radiation.
Alternatively, 5-FU/cisplatin can be given with concurrent radiation (category 2B).
All patients should receive a minimum RT dose of 45 Gy to the primary cancer.
Patients are re-evaluated using DRE between 8 and 12 weeks after completion of chemoRT.
Following re-evaluation, patients are classified according to whether they have a complete remission of disease, persistent disease, or progressive disease.

View source ↗